YEAR-END REPORT 2007

January - December 2007
• Group revenues from sales of goods and royalties amounted to 1,317.6 (1,303.7) MSEK during the year.

• Growth within the Esthetics product area was 13 percent and revenues amounted to 1,073.0 (950.6) MSEK.

• When Restylane Perlane was approved for sales in the USA (May 2007) Q-Med received 29.1 MUSD (199.7 MSEK) from Medicis.

• Operating income amounted to 370.5 (300.0) MSEK.

• Income after tax amounted to 315.4 (212.4) MSEK.

• Earnings per share after full dilution were 3.17 (2.14) SEK.

October - December 2007
• Group revenues from sales of goods and royalties amounted to335.9 (331.5) MSEK and operating income amounted to -10.7 (40.8) MSEK.

• Income after tax amounted to -13.7 (25.7) MSEK.

Important events after the end of the year
• An international distribution agreement has been entered into with Palomar Medical Technologies Inc. with regard to the marketing, sales and distribution of Palomar’s products outside North America (January 2008).

• Q-Med has decided to terminate production and sales of ZUIDEX and will offer DEFLUX for cystoscopic treatment of stress urinary incontinence (February 2008).

Queries should be addressed to:
Bengt Ågerup, President and CEO
Tel: +46 (0)70-974 9025
Madelene Sandgren, Director Investor Relations and Corporate Communications
Tel:+46 ( 0)70-974 9015